Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DNLI Denali Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DNLI
Price (delayed)
$14.8
Market cap
$2.15B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.68
Enterprise value
$2.14B
Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing
Highlights
Denali Therapeutics's debt has decreased by 3.9% from the previous quarter and by 3.8% YoY
The quick ratio has declined by 22% year-on-year but it has grown by 9% since the previous quarter
The EPS has plunged by 188% YoY and by 4.3% from the previous quarter
Denali Therapeutics's gross profit has shrunk by 100% YoY
Key stats
What are the main financial stats of DNLI
Market
Valuations
Earnings
Shares outstanding
145.28M
Market cap
$2.15B
Enterprise value
$2.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$515.21M
Net income
-$453.94M
EBIT
-$453.87M
EBITDA
-$443.83M
Free cash flow
-$384.38M
Per share
Balance sheet
Liquidity
EPS
-$2.68
EPS diluted
-$2.68
Free cash flow per share
-$2.24
Book value per share
$7.73
Revenue per share
$0
TBVPS
$7.43
Total assets
$1.27B
Total liabilities
$148.66M
Debt
$48.63M
Equity
$1.12B
Working capital
$786.76M
Debt to equity
0.04
Current ratio
9.56
Quick ratio
8.9
Net debt/EBITDA
0.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-32.4%
Return on equity
-35.9%
Return on invested capital
-36%
Return on capital employed
-38.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DNLI stock price
How has the Denali Therapeutics stock price performed over time
Intraday
2.99%
1 week
-7.44%
1 month
16.54%
1 year
-19.17%
YTD
-27.38%
QTD
8.86%
Financial performance
How have Denali Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$515.21M
Net income
-$453.94M
Gross margin
N/A
Net margin
N/A
DNLI's operating income has dropped by 166% year-on-year and by 6% since the previous quarter
Denali Therapeutics's gross profit has shrunk by 100% YoY
DNLI's revenue has dropped by 100% year-on-year
The net income is down by 7% since the previous quarter
Price vs fundamentals
How does DNLI's price correlate with its fundamentals
Growth
What is Denali Therapeutics's growth rate over time
Valuation
What is Denali Therapeutics stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has plunged by 188% YoY and by 4.3% from the previous quarter
DNLI's price to book (P/B) is 56% less than its 5-year quarterly average of 4.3 and 20% less than its last 4 quarters average of 2.4
Denali Therapeutics's equity has decreased by 23% YoY and by 9% QoQ
DNLI's revenue has dropped by 100% year-on-year
Efficiency
How efficient is Denali Therapeutics business performance
The return on equity has declined by 14% since the previous quarter
The return on invested capital has declined by 14% since the previous quarter
The return on assets has declined by 13% since the previous quarter
Dividends
What is DNLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DNLI.
Financial health
How did Denali Therapeutics financials performed over time
The quick ratio has declined by 22% year-on-year but it has grown by 9% since the previous quarter
The company's total assets fell by 20% YoY and by 7% QoQ
Denali Therapeutics's debt is 96% less than its equity
DNLI's debt to equity is up by 33% year-on-year
Denali Therapeutics's equity has decreased by 23% YoY and by 9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.